viewValiRx PLC

Company Update & Change of Adviser

/**/ p{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}link{ color: blue }visited{ color: #954F72 } .t{size:596.0pt 842.0pt;margin:56.75pt 64.4pt 14.0pt 62.0pt;}div.t{}p.ax{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:59.25pt;line-height:150%}span.av{font-size:10.0pt;line-height:150%;font-family:"Calibri","sans-serif"}p.ay{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 150%; margin-right: 59.25pt}span.at{font-size:10.0pt;line-height:150%}p.az{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 150%; margin-right: 59.25pt; text-align: center}span.ar{font-size:10.0pt; line-height:150%}p.ba{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 150%; margin-right: 59.25pt; text-align: center}span.ap{font-size:10.0pt;line-height: 150%} span.an{font-size:10.0pt; line-height:150%;letter-spacing:.1pt}p.bb{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%}span.am{font-size:10.0pt; line-height:150%;font-family:"Calibri","sans-serif"}p.bc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;line-height:150%}span.ak{letter-spacing:.05pt}span.aj{font-size:10.0pt;line-height:150%;font-family:"Calibri","sans-serif"; letter-spacing:.05pt}span.ah{font-size:10.0pt;line-height:150%;font-family:"Calibri","sans-serif"; background:white}p.bd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";line-height:150%}p.af{ font-weight: bold; line-height: 150%}p.ae{ font-weight: bold; line-height: 150%; text-align: center} p.be{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold; line-height: 150%}span.ad{font-size:10.0pt; line-height:150%;font-family:"Calibri","sans-serif";color:windowtext}table.bf{margin-left:-5.4pt;border-collapse:collapse}td.ab{width:260.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.bg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; margin: 0cm; margin-bottom: .0001pt}td.z{width:168.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.bh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;line-height:150%}span.bi{font-family: "Calibri","sans-serif"; font-size: 10.0pt; font-weight: bold; line-height: 150%}p.bj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; margin-bottom: 10.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 0cm}p.bk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; line-height: 150%} span.u{text-transform:uppercase}p.bl{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:8.0pt;font-family:"LyonText-Semibold","serif";color:black;line-height:150%} /**/
RNS Number : 9755H
ValiRx PLC
06 August 2019





("ValiRx", the "Company" or the "Group")


Company Update and Change of Adviser


London, UK., 06 August 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that, further to the announcements released by the Company on 2 May 2019 and 25 June 2019, the discussions for the intention to form the joint venture with Alpha Blue Ocean have not progressed and will be considered along with other opportunities.


The Company also announces that further to the notification of 25 June 2019, the Company is still waiting on receipt of the R&D tax credit of £400,000 from HMRC. The Company expects to receive this amount shortly. As a result, the Company continues to carefully manage its working capital position. A further notification will be made in due course.


The Company notes that SVS Securities plc ("SVS") has been placed into Special Administration. As a consequence, Novum Securities Limited is now the Company's sole broker with immediate effect.


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


*** ENDS ***


For more information, please contact:


ValiRx plc

Tel: +44 (0) 20 3008 4416


Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

[email protected]

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Novum Securities Limited (Broker)

Colin Rowbury

Tel: +44 (0) 20 7399 9400


Notes for Editors


About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.


The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field.


ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.


Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.


The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: ValiRx PLC

Price: 0.109

Market: AIM
Market Cap: £1.67 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19